Wells Fargo analyst Jim Birchenough says a meeting with Global Blood Therapeutics management has increased his confidence in the company's approval chances. The focus of the meeting was on recent pivotal data for hemoglobin modifier voxelotor in Sickle Cell Disease, plans for accelerated approval filing and confirmatory study and pre commercial preparation, Birchenough tells investors in a research note. He left with continued confidence in the strength of the company's data, the likelihood of an early 2020 approval and its commercial opportunity. The analyst keeps an Outperform rating on Global Blood.